董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Eric Easom | 男 | President, Chief Executive Officer, Chair and Director | 58 | 138.30万 | 228.69 | 2026-02-01 |
| Kabeer Aziz | 男 | Independent Director | 36 | 5.79万 | 255.41 | 2026-02-01 |
| Gilbert Lynn Marks | 男 | Independent Director | 68 | 5.79万 | 20.37 | 2026-02-01 |
| Patricia Martin | 女 | Independent Director | 65 | 7.22万 | 15.96 | 2026-02-01 |
| Rob Readnour | -- | Independent Director | 61 | 6.84万 | 137.20 | 2026-02-01 |
| Melvin Spigelman | -- | Independent Director | 77 | 6.79万 | 13.47 | 2026-02-01 |
| Margaret FitzPatrick | 女 | Independent Director | 59 | 8.94万 | 13.78 | 2026-02-01 |
| Joseph Zakrzewski | 男 | Independent Director | 63 | 7.19万 | 76.91 | 2026-02-01 |
| Stephanie Wong | 女 | Independent Director | 52 | 7.94万 | 14.27 | 2026-02-01 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Eric Easom | 男 | President, Chief Executive Officer, Chair and Director | 58 | 138.30万 | 228.69 | 2026-02-01 |
| Lucy Day | 女 | Chief Financial Officer | 67 | 77.43万 | 38.25 | 2026-02-01 |
| Joshua Eizen | 男 | Chief Legal Officer and Chief Operating Officer | 47 | 80.71万 | 未持股 | 2026-02-01 |
| Stephen Prior | -- | Chief Strategy Officer | 67 | 未披露 | 未持股 | 2026-02-01 |
| Sarah Williams | 女 | Vice President, Controller and Principal Accounting Officer | 38 | 未披露 | 未持股 | 2026-02-01 |
| Sanjay Chanda | 男 | Chief Development Officer | 61 | 未披露 | 未持股 | 2026-02-01 |
董事简历
中英对照 | 中文 | 英文- Eric Easom
-
ERIC Easom自2019年11月起担任我们的总裁兼首席执行官兼董事会成员。从2009年2月至2017年6月，Easom先生担任Anacor Pharmaceuticals, Inc.或Anacor的副总裁，该公司是一家上市的生物制药公司，被辉瑞公司收购。从2007年7月到2009年1月，Easom先生担任生物制药公司Intekrin Therapeutics，Inc.的业务开发和营销高级总监。从2006年4月到2007年7月，他担任MedImmune的营销总监，这是一家被阿斯利康收购的生物技术公司。Easom先生目前担任Chagas Disease Foundation和Resilient Biotics的董事会成员，并且是加州生命科学研究所的顾问。Easom先生在路易斯维尔大学获得电气工程学士学位和硕士学位，并在印第安纳大学凯利商学院获得工商管理硕士学位。
Eric Easom,served as Vice President, Neglected Diseases at Anacor Pharmaceuticals, Inc. ("Anacor"), a publicly traded biopharmaceutical company that was acquired by Pfizer Inc. From July 2007 to January 2009, Mr. Easom served as the Senior Director, Business Development and Marketing at InteKrin Therapeutics, Inc., a biopharmaceutical company. From April 2006 to July 2007, he served as the Director of Marketing at MedImmune, a biotechnology company that was acquired by AstraZeneca. Mr. Easom currently serves as a member of the board of directors of the Chagas Disease Foundation and Resilient Biotics, Inc., a private microbiome-based therapeutics company, and is an advisor for the California Life Sciences Institute. Mr. Easom received a B.S. and M.S. in Electrical Engineering from the University of Louisville and an M.B.A. from Indiana University, Kelley School of Business. - ERIC Easom自2019年11月起担任我们的总裁兼首席执行官兼董事会成员。从2009年2月至2017年6月，Easom先生担任Anacor Pharmaceuticals, Inc.或Anacor的副总裁，该公司是一家上市的生物制药公司，被辉瑞公司收购。从2007年7月到2009年1月，Easom先生担任生物制药公司Intekrin Therapeutics，Inc.的业务开发和营销高级总监。从2006年4月到2007年7月，他担任MedImmune的营销总监，这是一家被阿斯利康收购的生物技术公司。Easom先生目前担任Chagas Disease Foundation和Resilient Biotics的董事会成员，并且是加州生命科学研究所的顾问。Easom先生在路易斯维尔大学获得电气工程学士学位和硕士学位，并在印第安纳大学凯利商学院获得工商管理硕士学位。
- Eric Easom,served as Vice President, Neglected Diseases at Anacor Pharmaceuticals, Inc. ("Anacor"), a publicly traded biopharmaceutical company that was acquired by Pfizer Inc. From July 2007 to January 2009, Mr. Easom served as the Senior Director, Business Development and Marketing at InteKrin Therapeutics, Inc., a biopharmaceutical company. From April 2006 to July 2007, he served as the Director of Marketing at MedImmune, a biotechnology company that was acquired by AstraZeneca. Mr. Easom currently serves as a member of the board of directors of the Chagas Disease Foundation and Resilient Biotics, Inc., a private microbiome-based therapeutics company, and is an advisor for the California Life Sciences Institute. Mr. Easom received a B.S. and M.S. in Electrical Engineering from the University of Louisville and an M.B.A. from Indiana University, Kelley School of Business.
- Kabeer Aziz
-
Kabeer Aziz自2019年11月起担任我们的董事会成员。2018年10月，阿齐兹先生共同创立了Adjuvant Capital，这是一家专注于全球公共卫生的生命科学投资基金，目前担任负责人，负责采购、执行和管理主要侧重于传染病疫苗和疗法的投资。Aziz先生目前担任Minervax APS，Pulmocide Ltd.，Quantoom Biosciences S.A.和Frontier Nutrition，Inc.的董事会成员，并担任益盛生物制药有限公司的董事会观察员，这是一家医疗保健公司。从2015年10月至2018年9月，阿齐兹先生是全球健康投资基金（一家医疗保健重点影响基金）的高级合伙人。在此之前，阿齐兹先生于2013年7月至2015年9月担任Metalmark Capital的投资顾问，并于2011年6月至2013年6月担任Greenhill & Co.的分析师。阿齐兹先生在纽约大学斯特恩商学院获得金融和经济学学士学位。
Kabeer Aziz,serves as a member of the board of directors of several private companies, including MinervaX ApS, Pulmocide Ltd., and Frontier Nutrition, Inc. From October 2015 to September 2018, Mr. Aziz was a Senior Associate at the Global Health Investment Fund, a healthcare focused impact fund. Prior to this, Mr. Aziz was an Investment Associate at Metalmark Capital from July 2013 to September 2015 as well as an Analyst at Greenhill & Co. from June 2011 to June 2013. Mr. Aziz received a B.S. in Finance and Economics from the Stern School of Business at New York University. - Kabeer Aziz自2019年11月起担任我们的董事会成员。2018年10月，阿齐兹先生共同创立了Adjuvant Capital，这是一家专注于全球公共卫生的生命科学投资基金，目前担任负责人，负责采购、执行和管理主要侧重于传染病疫苗和疗法的投资。Aziz先生目前担任Minervax APS，Pulmocide Ltd.，Quantoom Biosciences S.A.和Frontier Nutrition，Inc.的董事会成员，并担任益盛生物制药有限公司的董事会观察员，这是一家医疗保健公司。从2015年10月至2018年9月，阿齐兹先生是全球健康投资基金（一家医疗保健重点影响基金）的高级合伙人。在此之前，阿齐兹先生于2013年7月至2015年9月担任Metalmark Capital的投资顾问，并于2011年6月至2013年6月担任Greenhill & Co.的分析师。阿齐兹先生在纽约大学斯特恩商学院获得金融和经济学学士学位。
- Kabeer Aziz,serves as a member of the board of directors of several private companies, including MinervaX ApS, Pulmocide Ltd., and Frontier Nutrition, Inc. From October 2015 to September 2018, Mr. Aziz was a Senior Associate at the Global Health Investment Fund, a healthcare focused impact fund. Prior to this, Mr. Aziz was an Investment Associate at Metalmark Capital from July 2013 to September 2015 as well as an Analyst at Greenhill & Co. from June 2011 to June 2013. Mr. Aziz received a B.S. in Finance and Economics from the Stern School of Business at New York University.
- Gilbert Lynn Marks
-
Gilbert Lynn Marks自2020年2月以来一直担任我们的董事会成员。从2017年9月到2021年9月，Marks博士受雇于Tunnell Government Services，Inc.或TGS，并于2020年1月成为TGS的副总裁，该公司是Tunnell Consulting，Inc.的子公司，为医疗产品开发的客户提供支持。作为TGS的员工，他曾担任生物医学高级研究与开发管理局（简称BARDA）主任办公室的承包商，该办公室是美国卫生与公共服务部的办公室，负责采购和开发化学，生物放射，核的医疗对策，以及包括新冠肺炎在内的大流行威胁。从2016年到2021年，马克斯博士担任国家转化科学促进中心（NCATS，美国国立卫生研究院的一个研究所）咨询委员会的成员。作为他对NCATS的支持的一部分，他还担任了治疗加速网络审查委员会的主席。从2006年到2018年，马克斯博士在非营利组织结核病联盟的科学顾问委员会任职，包括担任主席。自2020年以来，他一直在非营利组织疟疾药物风险投资的科学审查委员会任职，并同意从2022年开始担任该委员会主席。自2009年以来，他一直在小儿麻痹症抗病毒倡议的科学咨询委员会任职。自2017年以来，Marks博士一直担任宾夕法尼亚州费城Woar的非营利强奸危机支持中心的董事会成员。1993年至2017年，马克斯博士在GSK（一家上市制药公司）担任多个职务，包括担任研究与开发高级副总裁以及药物研究与开发领导团队的成员。他也曾担任GSK公司的传染病高级临床顾问。Marks博士在奥本大学获得化学学士学位，在南阿拉巴马大学医学院获得医学博士学位。他是内科和感染症的认证医师。
Gilbert Lynn Marks,served as a contractor supporting the Office of the Director for the Biomedical Advanced Research and Development Authority ("BARDA"), a U.S. Department of Health and Human Services office responsible for the procurement and development of medical countermeasures for chemical, biological, radiological, nuclear and pandemic threats. Subsequently, from 2023 to 2024, he served as an independent contractor for TGS and supported the Influenza and Emerging Infectious Diseases team within BARDA. From 2016 to 2021, Dr. Marks served as an SGE as a member of the Advisory Committee for the National Center for Advancing Translational Sciences ("NCATS"), an institute at the National Institutes of Health. As part of his support for NCATS, he also served as chair of the Cures Acceleration Network Review Board. From 2006 to 2018, Dr. Marks also served on the Scientific Advisory Board for the TB Alliance, a not-for-profit organization, including serving as chair. Since 2020, he has served on the Scientific Review Board for the Medicines for Malaria Venture ("MMV"), a not-for-profit organization, and has chaired the Development Committee of MMV since 2022. Since 2009, he has served on the Scientific Advisory Committee for the Polio Antiviral Initiative. Since 2022, he has served as a consultant to Virodefense, a biotech firm focused on antivirals for poliovirus. From 2017 to 2021, Dr. Marks served as a member of the board of directors for WOAR, a not-for-profit rape crisis support center. Previously, from 1993 to 2017, Dr. Marks served in multiple roles at GlaxoSmithKline (now GSK), a publicly traded pharmaceutical company, including serving as Senior Vice President in Research & Development and as a member of the Pharmaceuticals R&D Leadership team. Dr. Marks received a B.S. in Chemistry from Auburn University and an M.D. from the University of South Alabama College of Medicine. He is Board Certified in Internal Medicine and Infectious Diseases. - Gilbert Lynn Marks自2020年2月以来一直担任我们的董事会成员。从2017年9月到2021年9月，Marks博士受雇于Tunnell Government Services，Inc.或TGS，并于2020年1月成为TGS的副总裁，该公司是Tunnell Consulting，Inc.的子公司，为医疗产品开发的客户提供支持。作为TGS的员工，他曾担任生物医学高级研究与开发管理局（简称BARDA）主任办公室的承包商，该办公室是美国卫生与公共服务部的办公室，负责采购和开发化学，生物放射，核的医疗对策，以及包括新冠肺炎在内的大流行威胁。从2016年到2021年，马克斯博士担任国家转化科学促进中心（NCATS，美国国立卫生研究院的一个研究所）咨询委员会的成员。作为他对NCATS的支持的一部分，他还担任了治疗加速网络审查委员会的主席。从2006年到2018年，马克斯博士在非营利组织结核病联盟的科学顾问委员会任职，包括担任主席。自2020年以来，他一直在非营利组织疟疾药物风险投资的科学审查委员会任职，并同意从2022年开始担任该委员会主席。自2009年以来，他一直在小儿麻痹症抗病毒倡议的科学咨询委员会任职。自2017年以来，Marks博士一直担任宾夕法尼亚州费城Woar的非营利强奸危机支持中心的董事会成员。1993年至2017年，马克斯博士在GSK（一家上市制药公司）担任多个职务，包括担任研究与开发高级副总裁以及药物研究与开发领导团队的成员。他也曾担任GSK公司的传染病高级临床顾问。Marks博士在奥本大学获得化学学士学位，在南阿拉巴马大学医学院获得医学博士学位。他是内科和感染症的认证医师。
- Gilbert Lynn Marks,served as a contractor supporting the Office of the Director for the Biomedical Advanced Research and Development Authority ("BARDA"), a U.S. Department of Health and Human Services office responsible for the procurement and development of medical countermeasures for chemical, biological, radiological, nuclear and pandemic threats. Subsequently, from 2023 to 2024, he served as an independent contractor for TGS and supported the Influenza and Emerging Infectious Diseases team within BARDA. From 2016 to 2021, Dr. Marks served as an SGE as a member of the Advisory Committee for the National Center for Advancing Translational Sciences ("NCATS"), an institute at the National Institutes of Health. As part of his support for NCATS, he also served as chair of the Cures Acceleration Network Review Board. From 2006 to 2018, Dr. Marks also served on the Scientific Advisory Board for the TB Alliance, a not-for-profit organization, including serving as chair. Since 2020, he has served on the Scientific Review Board for the Medicines for Malaria Venture ("MMV"), a not-for-profit organization, and has chaired the Development Committee of MMV since 2022. Since 2009, he has served on the Scientific Advisory Committee for the Polio Antiviral Initiative. Since 2022, he has served as a consultant to Virodefense, a biotech firm focused on antivirals for poliovirus. From 2017 to 2021, Dr. Marks served as a member of the board of directors for WOAR, a not-for-profit rape crisis support center. Previously, from 1993 to 2017, Dr. Marks served in multiple roles at GlaxoSmithKline (now GSK), a publicly traded pharmaceutical company, including serving as Senior Vice President in Research & Development and as a member of the Pharmaceuticals R&D Leadership team. Dr. Marks received a B.S. in Chemistry from Auburn University and an M.D. from the University of South Alabama College of Medicine. He is Board Certified in Internal Medicine and Infectious Diseases.
- Patricia Martin
-
Patricia Martin自2021年4月起担任我们的董事会成员。自2019年7月以来，Martin女士一直担任BioCrossRoads的总裁兼首席执行官，BioCrossRoads是一家支持和促进印第安纳州生命科学行业的非营利组织。自2019年7月以来，Martin女士还担任BC Initiative，Inc.的管理合伙人，该公司支持生命科学领域的种子基金投资。从1991年6月至2017年6月，Martin女士在礼来公司（一家上市制药公司）或礼来公司担任多个职位，包括礼来糖尿病首席运营官，首席多元化官和首席联盟官。Martin女士目前还担任CaResource，Inc.，Flame Biosciences，Inc.，Indiana Biosciences Research Institute，Indiana Health Information Exchange，Indiana University Foundation，Indiana University Research and Technology Corporation，Regenstrief Institute和Christian Theological Seminary的董事会成员。Martin女士在印第安纳大学凯利商学院获得会计学学士学位，并在哈佛商学院获得工商管理硕士学位。
Patricia Martin,served as the President and Chief Executive Officer of BioCrossroads, a not-for-profit organization that supports and promotes the life sciences industry in the state of Indiana, and served as the Managing Partner of BC Initiative, Inc., a company that supports seed fund investing in life sciences. From June 1991 to June 2017, Ms. Martin held multiple positions at Eli Lilly and Company ("Eli Lilly"), a publicly traded pharmaceutical company, including Chief Operations Officer of Lilly Diabetes, Chief Diversity Officer and Chief Alliance Officer. Ms. Martin currently also serves as a member of the board of directors of Leap Therapeutics, Inc., a Nasdaq listed immuno-oncology company, and several private companies, including Indiana University Foundation, Indiana University - Simon Comprehensive Cancer Center, P2K Dynamics, Inc. and Regenstrief Institute. Ms. Martin received a B.S. in Accounting from the Kelley School of Business at Indiana University and an M.B.A. from Harvard Business School. - Patricia Martin自2021年4月起担任我们的董事会成员。自2019年7月以来，Martin女士一直担任BioCrossRoads的总裁兼首席执行官，BioCrossRoads是一家支持和促进印第安纳州生命科学行业的非营利组织。自2019年7月以来，Martin女士还担任BC Initiative，Inc.的管理合伙人，该公司支持生命科学领域的种子基金投资。从1991年6月至2017年6月，Martin女士在礼来公司（一家上市制药公司）或礼来公司担任多个职位，包括礼来糖尿病首席运营官，首席多元化官和首席联盟官。Martin女士目前还担任CaResource，Inc.，Flame Biosciences，Inc.，Indiana Biosciences Research Institute，Indiana Health Information Exchange，Indiana University Foundation，Indiana University Research and Technology Corporation，Regenstrief Institute和Christian Theological Seminary的董事会成员。Martin女士在印第安纳大学凯利商学院获得会计学学士学位，并在哈佛商学院获得工商管理硕士学位。
- Patricia Martin,served as the President and Chief Executive Officer of BioCrossroads, a not-for-profit organization that supports and promotes the life sciences industry in the state of Indiana, and served as the Managing Partner of BC Initiative, Inc., a company that supports seed fund investing in life sciences. From June 1991 to June 2017, Ms. Martin held multiple positions at Eli Lilly and Company ("Eli Lilly"), a publicly traded pharmaceutical company, including Chief Operations Officer of Lilly Diabetes, Chief Diversity Officer and Chief Alliance Officer. Ms. Martin currently also serves as a member of the board of directors of Leap Therapeutics, Inc., a Nasdaq listed immuno-oncology company, and several private companies, including Indiana University Foundation, Indiana University - Simon Comprehensive Cancer Center, P2K Dynamics, Inc. and Regenstrief Institute. Ms. Martin received a B.S. in Accounting from the Kelley School of Business at Indiana University and an M.B.A. from Harvard Business School.
- Rob Readnour
-
Rob Readnour自2019年11月起担任我们的董事会成员。自2018年7月以来，Readnour博士一直担任Mountain Group Partners的董事总经理，该公司是一家风险投资公司，致力于投资生命科学，农业技术和技术领域的早期公司。1990年10月至2018年6月，Readnour博士在Elanco Animal Health Incorporated担任多个高级管理职位，Elanco Animal Health Incorporated是一家上市制药公司，之前是礼来公司的一部分，包括Elanco Alternative Innovation的产品开发高级总监和高级顾问兼首席科学官。Readnour博士目前担任Targan Inc.（一家专注于动物健康的生物系统公司）、Advanced Animal Diagnostics，Inc（一家动物健康设备公司）、Skyline VET制药公司（一家兽医制药公司）、Exubrion Therapeutics，Inc.的董事会成员或拥有访问权，一家放射治疗兽医设备公司、药物开发公司Appello Pharmaceuticals，Inc.和药物和营养化合物开发公司Nusirt Biopharma，Inc.。Readnour博士目前还担任动物保健公司In the Bowl Animal Health，Inc.的执行主席。Readnour博士也是Borah，Inc.（一家动物健康发现公司）的首席执行官。Readnour博士在伊利诺伊大学获得分析化学博士学位，在东南密苏里州立大学获得化学学士学位。
Rob Readnour,served in multiple senior management positions at Elanco Animal Health Incorporated, a publicly traded pharmaceutical company that was previously part of Eli Lilly & Co., including Senior Director of Product Development and Senior Advisor and Chief Scientific Officer at Elanco Alternative Innovation. Dr. Readnour currently serves as a member of the board of or has visitation rights to several private companies, including Advanced Animal Diagnostics, a diagnostics company developing point-of-care tests across various human and animal applications, Targan, a bio-systems company focused on animal health, Vytelle and Verility, animal health fertility companies, Velo-1, an animal health drug development company building a portfolio of high-value prescription medicines for companion animals, Skyline Vet Pharma, a veterinary pharmaceutical company, and Exubrion Therapeutics, a radiotherapeutic veterinary device company. Dr. Readnour also currently serves as the Chairman of In the Bowl Animal Health, Inc., an animal health company, and serves as Executive Chairman of Borah, an animal health discovery company. Dr. Readnour received a Ph.D. in Analytical Chemistry from University of Illinois and a B.S. in Chemistry from Southeast Missouri State University. - Rob Readnour自2019年11月起担任我们的董事会成员。自2018年7月以来，Readnour博士一直担任Mountain Group Partners的董事总经理，该公司是一家风险投资公司，致力于投资生命科学，农业技术和技术领域的早期公司。1990年10月至2018年6月，Readnour博士在Elanco Animal Health Incorporated担任多个高级管理职位，Elanco Animal Health Incorporated是一家上市制药公司，之前是礼来公司的一部分，包括Elanco Alternative Innovation的产品开发高级总监和高级顾问兼首席科学官。Readnour博士目前担任Targan Inc.（一家专注于动物健康的生物系统公司）、Advanced Animal Diagnostics，Inc（一家动物健康设备公司）、Skyline VET制药公司（一家兽医制药公司）、Exubrion Therapeutics，Inc.的董事会成员或拥有访问权，一家放射治疗兽医设备公司、药物开发公司Appello Pharmaceuticals，Inc.和药物和营养化合物开发公司Nusirt Biopharma，Inc.。Readnour博士目前还担任动物保健公司In the Bowl Animal Health，Inc.的执行主席。Readnour博士也是Borah，Inc.（一家动物健康发现公司）的首席执行官。Readnour博士在伊利诺伊大学获得分析化学博士学位，在东南密苏里州立大学获得化学学士学位。
- Rob Readnour,served in multiple senior management positions at Elanco Animal Health Incorporated, a publicly traded pharmaceutical company that was previously part of Eli Lilly & Co., including Senior Director of Product Development and Senior Advisor and Chief Scientific Officer at Elanco Alternative Innovation. Dr. Readnour currently serves as a member of the board of or has visitation rights to several private companies, including Advanced Animal Diagnostics, a diagnostics company developing point-of-care tests across various human and animal applications, Targan, a bio-systems company focused on animal health, Vytelle and Verility, animal health fertility companies, Velo-1, an animal health drug development company building a portfolio of high-value prescription medicines for companion animals, Skyline Vet Pharma, a veterinary pharmaceutical company, and Exubrion Therapeutics, a radiotherapeutic veterinary device company. Dr. Readnour also currently serves as the Chairman of In the Bowl Animal Health, Inc., an animal health company, and serves as Executive Chairman of Borah, an animal health discovery company. Dr. Readnour received a Ph.D. in Analytical Chemistry from University of Illinois and a B.S. in Chemistry from Southeast Missouri State University.
- Melvin Spigelman
-
Melvin Spigelman自2022年2月起担任我们的董事会成员。自2009年1月以来，Spigelman博士一直担任全球结核病药物开发联盟的总裁兼首席执行官，该联盟是一个非营利组织，旨在加速发现和开发快速有效和负担得起的结核病药物。从2003年6月到2008年6月，Spigelman博士担任全球结核药物开发联盟研究与开发的董事。从2001年6月到2003年6月，Spigelman博士还担任Hudson-Douglas Ltd的总裁，这是一家咨询公司。从2000年到2001年，Spigelman博士担任Knoll Pharmaceuticals的全球临床中心副总裁，这是巴斯夫公司的制药部门，从1992年到2000年，Spigelman博士担任Knoll Pharmaceuticals的研究与开发副总裁。Spigelman博士于2005年至2018年担任制药公司The Medicines Company的董事，并于2005年至2019年担任制药公司Synergy Pharmaceuticals Inc.的董事。斯皮格尔曼博士在布朗大学获得工程学士学位，在西奈山医学院获得医学博士学位。
Melvin Spigelman,has served as President and Chief Executive Officer for the Global Alliance for TB Drug Development, a non-profit organization which seeks to accelerate the discovery and development of faster-acting and affordable drugs to fight tuberculosis. From June 2003 to June 2008, Dr. Spigelman served as a Director of Research and Development for the Global Alliance for TB Drug Development. Dr. Spigelman was also President of Hudson-Douglas Ltd, a consulting company, from June 2001 to June 2003. From 2000 to 2001, Dr. Spigelman served as a Vice President, Global Clinical Centers at Knoll Pharmaceuticals, a pharmaceutical unit of BASF Corporation, and from 1992 to 2000, Dr. Spigelman was the Vice President of Research and Development at Knoll Pharmaceuticals. Dr. Spigelman served as a director of The Medicines Company, a pharmaceutical company, from 2005 to 2018 and as director of Synergy Pharmaceuticals Inc., a pharmaceutical company, from 2005 to 2019. Dr. Spigelman received a B.A. in Engineering from Brown University and an M.D. from the Mount Sinai School of Medicine. - Melvin Spigelman自2022年2月起担任我们的董事会成员。自2009年1月以来，Spigelman博士一直担任全球结核病药物开发联盟的总裁兼首席执行官，该联盟是一个非营利组织，旨在加速发现和开发快速有效和负担得起的结核病药物。从2003年6月到2008年6月，Spigelman博士担任全球结核药物开发联盟研究与开发的董事。从2001年6月到2003年6月，Spigelman博士还担任Hudson-Douglas Ltd的总裁，这是一家咨询公司。从2000年到2001年，Spigelman博士担任Knoll Pharmaceuticals的全球临床中心副总裁，这是巴斯夫公司的制药部门，从1992年到2000年，Spigelman博士担任Knoll Pharmaceuticals的研究与开发副总裁。Spigelman博士于2005年至2018年担任制药公司The Medicines Company的董事，并于2005年至2019年担任制药公司Synergy Pharmaceuticals Inc.的董事。斯皮格尔曼博士在布朗大学获得工程学士学位，在西奈山医学院获得医学博士学位。
- Melvin Spigelman,has served as President and Chief Executive Officer for the Global Alliance for TB Drug Development, a non-profit organization which seeks to accelerate the discovery and development of faster-acting and affordable drugs to fight tuberculosis. From June 2003 to June 2008, Dr. Spigelman served as a Director of Research and Development for the Global Alliance for TB Drug Development. Dr. Spigelman was also President of Hudson-Douglas Ltd, a consulting company, from June 2001 to June 2003. From 2000 to 2001, Dr. Spigelman served as a Vice President, Global Clinical Centers at Knoll Pharmaceuticals, a pharmaceutical unit of BASF Corporation, and from 1992 to 2000, Dr. Spigelman was the Vice President of Research and Development at Knoll Pharmaceuticals. Dr. Spigelman served as a director of The Medicines Company, a pharmaceutical company, from 2005 to 2018 and as director of Synergy Pharmaceuticals Inc., a pharmaceutical company, from 2005 to 2019. Dr. Spigelman received a B.A. in Engineering from Brown University and an M.D. from the Mount Sinai School of Medicine.
- Margaret FitzPatrick
-
Margaret FitzPatrick，一直是提供战略咨询服务的商业咨询服务公司FitzPatrick & Co.的创始人兼首席执行官。2016年至2020年，FitzPatrick女士担任《财富》200强清洁能源供应商爱克斯龙的首席公司事务官。2013年至2016年，她担任强生首席传播官兼公共事务副总裁。2010年至2013年，FitzPatrick女士在信诺担任首席传播官兼基金会总裁。在此之前，FitzPatrick女士曾在全球公共事务和战略传播咨询公司APCO Worldwide担任多个职位，包括执行副总裁。FitzPatrick女士是VistaGen Therapeutics的董事会主席，VistaGen Therapeutics是一家在纳斯达克上市、专注于中枢神经系统晚期的生物制药公司。FitzPatrick女士拥有雪城大学英语和公共政策学士学位和乔治华盛顿大学公共政策硕士学位。她在哈佛商学院完成了董事会董事课程，并被美国全国公司董事协会认证为公司董事。
Margaret FitzPatrick,has been the Founder and Chief Executive Officer of FitzPatrick & Co., a business advisory services firm providing strategic advisory services. From 2016 to 2020, Ms. FitzPatrick served as Chief Corporate Affairs Officer for Exelon, a Fortune 200 clean energy provider. From 2013 to 2016, she served as Chief Communications Officer and VP of Public Affairs at Johnson & Johnson. From 2010 to 2013, Ms. FitzPatrick served as Chief Communications Officer and President of the Foundation at Cigna. Prior to that, Ms. FitzPatrick held multiple positions at APCO Worldwide, a global public affairs and strategic communications consultancy, including Executive Vice President. Ms. FitzPatrick is Chair of the board of directors at VistaGen Therapeutics, a Nasdaq listed, late-stage central nervous system-focused biopharmaceutical company. Ms. FitzPatrick holds a B.A. in English and Public Policy from Syracuse University and a M.A. in Public Policy from The George Washington University. She completed the board directorship program at the Harvard Business School and is certified as a corporate director by the National Association of Corporate Directors. - Margaret FitzPatrick，一直是提供战略咨询服务的商业咨询服务公司FitzPatrick & Co.的创始人兼首席执行官。2016年至2020年，FitzPatrick女士担任《财富》200强清洁能源供应商爱克斯龙的首席公司事务官。2013年至2016年，她担任强生首席传播官兼公共事务副总裁。2010年至2013年，FitzPatrick女士在信诺担任首席传播官兼基金会总裁。在此之前，FitzPatrick女士曾在全球公共事务和战略传播咨询公司APCO Worldwide担任多个职位，包括执行副总裁。FitzPatrick女士是VistaGen Therapeutics的董事会主席，VistaGen Therapeutics是一家在纳斯达克上市、专注于中枢神经系统晚期的生物制药公司。FitzPatrick女士拥有雪城大学英语和公共政策学士学位和乔治华盛顿大学公共政策硕士学位。她在哈佛商学院完成了董事会董事课程，并被美国全国公司董事协会认证为公司董事。
- Margaret FitzPatrick,has been the Founder and Chief Executive Officer of FitzPatrick & Co., a business advisory services firm providing strategic advisory services. From 2016 to 2020, Ms. FitzPatrick served as Chief Corporate Affairs Officer for Exelon, a Fortune 200 clean energy provider. From 2013 to 2016, she served as Chief Communications Officer and VP of Public Affairs at Johnson & Johnson. From 2010 to 2013, Ms. FitzPatrick served as Chief Communications Officer and President of the Foundation at Cigna. Prior to that, Ms. FitzPatrick held multiple positions at APCO Worldwide, a global public affairs and strategic communications consultancy, including Executive Vice President. Ms. FitzPatrick is Chair of the board of directors at VistaGen Therapeutics, a Nasdaq listed, late-stage central nervous system-focused biopharmaceutical company. Ms. FitzPatrick holds a B.A. in English and Public Policy from Syracuse University and a M.A. in Public Policy from The George Washington University. She completed the board directorship program at the Harvard Business School and is certified as a corporate director by the National Association of Corporate Directors.
- Joseph Zakrzewski
-
Joseph Zakrzewski自2017年5月起担任AN2 Therapeutics公司董事会成员。Zakrzewski先生目前担任生物制药公司Cerecin，Inc.和上市生物技术公司Cyteir Therapeutics, Inc.的Shlomo Kramer。Zakrzewski先生目前还担任上市生物制药公司Amarin Corporation或Amarin的董事会成员。2014年至2020年，Zakrzewski先生担任制药公司SiteOne Therapeutics，Inc.的董事会成员。2009年12月至2013年12月，Zakrzewski先生还担任Amarin的董事长兼首席执行官。Zakrzewski先生获得了学士学位。德雷塞尔大学化学工程学士，硕士德雷塞尔大学生化工程学士学位和印第安纳大学金融学工商管理硕士学位。
Joseph Zakrzewski,served as a member of the board of directors at Sangamo Therapeutics, Inc., a publicly traded biotechnology company, and Acceleron Pharma, a publicly traded biotechnology company. From December 2009 to June 2022, Mr. Zakrzewski served as a member of the board of directors of Amarin Corporation, a publicly traded biopharmaceutical company ("Amarin"). From 2014 to 2020, Mr. Zakrzewski served as a member of the board of directors of SiteOne Therapeutics, Inc., a pharmaceutical company. From December 2009 to December 2013, Mr. Zakrzewski also served as the Chairman and Chief Executive Officer of Amarin. Mr. Zakrzewski received a B.S. in Chemical Engineering from Drexel University, an M.S. in Biochemical Engineering from Drexel University, and an M.B.A. in Finance from Indiana University. - Joseph Zakrzewski自2017年5月起担任AN2 Therapeutics公司董事会成员。Zakrzewski先生目前担任生物制药公司Cerecin，Inc.和上市生物技术公司Cyteir Therapeutics, Inc.的Shlomo Kramer。Zakrzewski先生目前还担任上市生物制药公司Amarin Corporation或Amarin的董事会成员。2014年至2020年，Zakrzewski先生担任制药公司SiteOne Therapeutics，Inc.的董事会成员。2009年12月至2013年12月，Zakrzewski先生还担任Amarin的董事长兼首席执行官。Zakrzewski先生获得了学士学位。德雷塞尔大学化学工程学士，硕士德雷塞尔大学生化工程学士学位和印第安纳大学金融学工商管理硕士学位。
- Joseph Zakrzewski,served as a member of the board of directors at Sangamo Therapeutics, Inc., a publicly traded biotechnology company, and Acceleron Pharma, a publicly traded biotechnology company. From December 2009 to June 2022, Mr. Zakrzewski served as a member of the board of directors of Amarin Corporation, a publicly traded biopharmaceutical company ("Amarin"). From 2014 to 2020, Mr. Zakrzewski served as a member of the board of directors of SiteOne Therapeutics, Inc., a pharmaceutical company. From December 2009 to December 2013, Mr. Zakrzewski also served as the Chairman and Chief Executive Officer of Amarin. Mr. Zakrzewski received a B.S. in Chemical Engineering from Drexel University, an M.S. in Biochemical Engineering from Drexel University, and an M.B.A. in Finance from Indiana University.
- Stephanie Wong
-
Stephanie Wong，2009年她加入赛生公司（SciClone）。她目前担任副总裁负责财务和财务总监。在加入赛生公司（SciClone）之前，她担任AcelRx Pharmaceuticals的高级董事负责财务。从2001年到2008年，她担任Kosan Biosciences（一个上市的生物科技公司，2008年被百时美施贵宝（Bristol-Myers Squibb）收购）各种职务，最后担任高级董事兼财务总监。此前，她担任普华永道（PricewaterhouseCoopers）的审计经理。她获得伯克利的加州大学（University of California）的工商管理学士学位。她是一个注册会计师。
Stephanie Wong,served in various roles at Calithera, including as Senior Vice President, Finance from January 2018 to December 2020 and as Vice President, Finance from April 2014 to December 2016. Since December 2016, she has also served as a member of the board of directors of the Northern California Chapter of The Association of Bioscience Financial Officers, an association for financial executives working in the bioscience industry. From 2009 to 2013, Ms. Wong served in various roles at SciClone Pharmaceuticals, Inc., a publicly traded pharmaceutical company, most recently as Vice President, Finance and Controller. Ms. Wong received a B.S. in Business Administration from the University of California, Berkeley and is a Certified Public Accountant (inactive) in the state of California. - Stephanie Wong，2009年她加入赛生公司（SciClone）。她目前担任副总裁负责财务和财务总监。在加入赛生公司（SciClone）之前，她担任AcelRx Pharmaceuticals的高级董事负责财务。从2001年到2008年，她担任Kosan Biosciences（一个上市的生物科技公司，2008年被百时美施贵宝（Bristol-Myers Squibb）收购）各种职务，最后担任高级董事兼财务总监。此前，她担任普华永道（PricewaterhouseCoopers）的审计经理。她获得伯克利的加州大学（University of California）的工商管理学士学位。她是一个注册会计师。
- Stephanie Wong,served in various roles at Calithera, including as Senior Vice President, Finance from January 2018 to December 2020 and as Vice President, Finance from April 2014 to December 2016. Since December 2016, she has also served as a member of the board of directors of the Northern California Chapter of The Association of Bioscience Financial Officers, an association for financial executives working in the bioscience industry. From 2009 to 2013, Ms. Wong served in various roles at SciClone Pharmaceuticals, Inc., a publicly traded pharmaceutical company, most recently as Vice President, Finance and Controller. Ms. Wong received a B.S. in Business Administration from the University of California, Berkeley and is a Certified Public Accountant (inactive) in the state of California.
高管简历
中英对照 | 中文 | 英文- Eric Easom
ERIC Easom自2019年11月起担任我们的总裁兼首席执行官兼董事会成员。从2009年2月至2017年6月，Easom先生担任Anacor Pharmaceuticals, Inc.或Anacor的副总裁，该公司是一家上市的生物制药公司，被辉瑞公司收购。从2007年7月到2009年1月，Easom先生担任生物制药公司Intekrin Therapeutics，Inc.的业务开发和营销高级总监。从2006年4月到2007年7月，他担任MedImmune的营销总监，这是一家被阿斯利康收购的生物技术公司。Easom先生目前担任Chagas Disease Foundation和Resilient Biotics的董事会成员，并且是加州生命科学研究所的顾问。Easom先生在路易斯维尔大学获得电气工程学士学位和硕士学位，并在印第安纳大学凯利商学院获得工商管理硕士学位。
Eric Easom,served as Vice President, Neglected Diseases at Anacor Pharmaceuticals, Inc. ("Anacor"), a publicly traded biopharmaceutical company that was acquired by Pfizer Inc. From July 2007 to January 2009, Mr. Easom served as the Senior Director, Business Development and Marketing at InteKrin Therapeutics, Inc., a biopharmaceutical company. From April 2006 to July 2007, he served as the Director of Marketing at MedImmune, a biotechnology company that was acquired by AstraZeneca. Mr. Easom currently serves as a member of the board of directors of the Chagas Disease Foundation and Resilient Biotics, Inc., a private microbiome-based therapeutics company, and is an advisor for the California Life Sciences Institute. Mr. Easom received a B.S. and M.S. in Electrical Engineering from the University of Louisville and an M.B.A. from Indiana University, Kelley School of Business.- ERIC Easom自2019年11月起担任我们的总裁兼首席执行官兼董事会成员。从2009年2月至2017年6月，Easom先生担任Anacor Pharmaceuticals, Inc.或Anacor的副总裁，该公司是一家上市的生物制药公司，被辉瑞公司收购。从2007年7月到2009年1月，Easom先生担任生物制药公司Intekrin Therapeutics，Inc.的业务开发和营销高级总监。从2006年4月到2007年7月，他担任MedImmune的营销总监，这是一家被阿斯利康收购的生物技术公司。Easom先生目前担任Chagas Disease Foundation和Resilient Biotics的董事会成员，并且是加州生命科学研究所的顾问。Easom先生在路易斯维尔大学获得电气工程学士学位和硕士学位，并在印第安纳大学凯利商学院获得工商管理硕士学位。
- Eric Easom,served as Vice President, Neglected Diseases at Anacor Pharmaceuticals, Inc. ("Anacor"), a publicly traded biopharmaceutical company that was acquired by Pfizer Inc. From July 2007 to January 2009, Mr. Easom served as the Senior Director, Business Development and Marketing at InteKrin Therapeutics, Inc., a biopharmaceutical company. From April 2006 to July 2007, he served as the Director of Marketing at MedImmune, a biotechnology company that was acquired by AstraZeneca. Mr. Easom currently serves as a member of the board of directors of the Chagas Disease Foundation and Resilient Biotics, Inc., a private microbiome-based therapeutics company, and is an advisor for the California Life Sciences Institute. Mr. Easom received a B.S. and M.S. in Electrical Engineering from the University of Louisville and an M.B.A. from Indiana University, Kelley School of Business.
- Lucy Day
LUCY Day自2019年11月起担任我们的首席财务官。从2002年3月到2016年8月，Day女士担任过各种财务和行政职务，包括担任Anacor的初始首席财务官，财务副总裁，副总裁，人力资源和财务。1994年2月至2002年1月，Day女士在Centaur Pharmaceuticals，Inc.（一家生物制药公司）担任各种财务职务，包括首席财务官。Day女士曾在美国银行，Sohio Petroleum Company和Ernst and Young LLP工作。Day女士获得了加州大学伯克利分校政治经济学学士学位，并在加利福尼亚州注册会计师。
Lucy Day,served in various financial and administrative roles, including as the initial Chief Financial Officer, Vice President of Finance, and Vice President, Human Resources and Finance at Anacor. Ms. Day has previous experience at Centaur Pharmaceuticals, Inc., a biopharmaceutical company, including as Chief Financial Officer, Bank of America, Sohio Petroleum Company, and Ernst and Young LLP. Ms. Day received a B.A. in Political Economies from the University of California, Berkeley and is a CPA (inactive) in California.- LUCY Day自2019年11月起担任我们的首席财务官。从2002年3月到2016年8月，Day女士担任过各种财务和行政职务，包括担任Anacor的初始首席财务官，财务副总裁，副总裁，人力资源和财务。1994年2月至2002年1月，Day女士在Centaur Pharmaceuticals，Inc.（一家生物制药公司）担任各种财务职务，包括首席财务官。Day女士曾在美国银行，Sohio Petroleum Company和Ernst and Young LLP工作。Day女士获得了加州大学伯克利分校政治经济学学士学位，并在加利福尼亚州注册会计师。
- Lucy Day,served in various financial and administrative roles, including as the initial Chief Financial Officer, Vice President of Finance, and Vice President, Human Resources and Finance at Anacor. Ms. Day has previous experience at Centaur Pharmaceuticals, Inc., a biopharmaceutical company, including as Chief Financial Officer, Bank of America, Sohio Petroleum Company, and Ernst and Young LLP. Ms. Day received a B.A. in Political Economies from the University of California, Berkeley and is a CPA (inactive) in California.
- Joshua Eizen
Joshua Eizen，曾担任爵士制药副总裁、副总法律顾问。2018年7月至2021年5月，Eizen先生担任副总裁，GW Pharmaceuticals PLC的美国总法律顾问。2015年5月至2018年6月，Eizen先生在Actelion Pharmaceuticals（现为杨森肺动脉高压）担任高级法律顾问、首席合规官。2008年8月至2014年10月，Eizen先生担任美国食品和药物管理局副首席法律顾问。此前，Eizen先生是McKee Nelson（现为Morgan Lewis）律师事务所的合伙人。Eizen先生在乔治敦大学法律中心获得法学博士学位，在凯斯西储大学获得政治学和政府学学士和硕士学位。
Joshua Eizen,served as Vice President, Associate General Counsel at Jazz Pharmaceuticals. From July 2018 to May 2021, Mr. Eizen served as Vice President, U.S. General Counsel for GW Pharmaceuticals plc. From May 2015 to June 2018, Mr. Eizen served as Senior Counsel, Chief Compliance Officer at Actelion Pharmaceuticals (now Janssen Pulmonary Hypertension). From August 2008 to October 2014, Mr. Eizen served as Associate Chief Counsel at the U.S. Food and Drug Administration. Previously, Mr. Eizen was an Associate with the law firm of McKee Nelson (now Morgan Lewis). Mr. Eizen received a J.D. from Georgetown University Law Center and a B.A. and M.A. in Political Science and Government from Case Western Reserve University.- Joshua Eizen，曾担任爵士制药副总裁、副总法律顾问。2018年7月至2021年5月，Eizen先生担任副总裁，GW Pharmaceuticals PLC的美国总法律顾问。2015年5月至2018年6月，Eizen先生在Actelion Pharmaceuticals（现为杨森肺动脉高压）担任高级法律顾问、首席合规官。2008年8月至2014年10月，Eizen先生担任美国食品和药物管理局副首席法律顾问。此前，Eizen先生是McKee Nelson（现为Morgan Lewis）律师事务所的合伙人。Eizen先生在乔治敦大学法律中心获得法学博士学位，在凯斯西储大学获得政治学和政府学学士和硕士学位。
- Joshua Eizen,served as Vice President, Associate General Counsel at Jazz Pharmaceuticals. From July 2018 to May 2021, Mr. Eizen served as Vice President, U.S. General Counsel for GW Pharmaceuticals plc. From May 2015 to June 2018, Mr. Eizen served as Senior Counsel, Chief Compliance Officer at Actelion Pharmaceuticals (now Janssen Pulmonary Hypertension). From August 2008 to October 2014, Mr. Eizen served as Associate Chief Counsel at the U.S. Food and Drug Administration. Previously, Mr. Eizen was an Associate with the law firm of McKee Nelson (now Morgan Lewis). Mr. Eizen received a J.D. from Georgetown University Law Center and a B.A. and M.A. in Political Science and Government from Case Western Reserve University.
- Stephen Prior
Stephen Prior曾担任Therax，Inc.总裁，作为国家安全问题和由新型、紧急或人为疾病引起的健康威胁的主题专家向美国政府提供建议，并于2006年1月至2024年12月担任美国国防大学（华盛顿特区）国家危急事件分析中心的执行主任。Prior博士获得了理学学士学位。英国肯特大学微生物学荣誉学位和英国华威大学微生物学博士学位。
Stephen Prior,has served as President of Therax, Inc., advising the U.S. government as a subject matter expert on national security issues and health threats that result from novel, emergent or man-made diseases and from January 2006 to December 2024 served as Executive Director at the National Center for Critical Incident Analysis at the National Defense University (Washington, DC). Dr. Prior received a B.Sc. Hons. in microbiology from University of Kent, U.K. and a Ph.D. in microbiology from Warwick University, U.K.- Stephen Prior曾担任Therax，Inc.总裁，作为国家安全问题和由新型、紧急或人为疾病引起的健康威胁的主题专家向美国政府提供建议，并于2006年1月至2024年12月担任美国国防大学（华盛顿特区）国家危急事件分析中心的执行主任。Prior博士获得了理学学士学位。英国肯特大学微生物学荣誉学位和英国华威大学微生物学博士学位。
- Stephen Prior,has served as President of Therax, Inc., advising the U.S. government as a subject matter expert on national security issues and health threats that result from novel, emergent or man-made diseases and from January 2006 to December 2024 served as Executive Director at the National Center for Critical Incident Analysis at the National Defense University (Washington, DC). Dr. Prior received a B.Sc. Hons. in microbiology from University of Kent, U.K. and a Ph.D. in microbiology from Warwick University, U.K.
- Sarah Williams
Sarah 威廉姆斯，于2018年8月至2024年5月期间在生物技术公司Gritstone Bio担任越来越重要的职务，最近一次担任财务总监。2016年8月至2018年8月，威廉姆斯女士在生物技术公司Bio-Rad Laboratories担任会计职务。此前，威廉姆斯女士于2012年11月至2016年3月担任会计师事务所BDO USA，LLP的鉴证经理，并于2010年8月至2012年11月担任会计和咨询公司Crowe Horwath LLP的鉴证服务高级助理。威廉姆斯女士拥有索诺玛州立大学会计学专业的商学学士学位，是一名注册会计师（非在职）。
Sarah Williams,held positions of increasing responsibility at Gritstone Bio, a biotechnology company, from August 2018 to May 2024, including most recently as Controller. From August 2016 to August 2018, Ms. Williams served in accounting roles at Bio-Rad Laboratories, a biotech company. Previously, Ms. Williams was Assurance Manager at BDO USA, LLP, an accounting firm, from November 2012 to March 2016 and a Senior Associate, Assurance Services at Crowe Horwath LLP, an accounting and consulting firm, from August 2010 to November 2012. Ms. Williams holds a Bachelor of Science in Business with a concentration in Accounting from Sonoma State University and is a Certified Public Accountant (inactive).- Sarah 威廉姆斯，于2018年8月至2024年5月期间在生物技术公司Gritstone Bio担任越来越重要的职务，最近一次担任财务总监。2016年8月至2018年8月，威廉姆斯女士在生物技术公司Bio-Rad Laboratories担任会计职务。此前，威廉姆斯女士于2012年11月至2016年3月担任会计师事务所BDO USA，LLP的鉴证经理，并于2010年8月至2012年11月担任会计和咨询公司Crowe Horwath LLP的鉴证服务高级助理。威廉姆斯女士拥有索诺玛州立大学会计学专业的商学学士学位，是一名注册会计师（非在职）。
- Sarah Williams,held positions of increasing responsibility at Gritstone Bio, a biotechnology company, from August 2018 to May 2024, including most recently as Controller. From August 2016 to August 2018, Ms. Williams served in accounting roles at Bio-Rad Laboratories, a biotech company. Previously, Ms. Williams was Assurance Manager at BDO USA, LLP, an accounting firm, from November 2012 to March 2016 and a Senior Associate, Assurance Services at Crowe Horwath LLP, an accounting and consulting firm, from August 2010 to November 2012. Ms. Williams holds a Bachelor of Science in Business with a concentration in Accounting from Sonoma State University and is a Certified Public Accountant (inactive).
- Sanjay Chanda
Sanjay Chanda，博士。自2012年3月至2013年10月任中期药品发展公司副总裁一职，随后自2013年10月成为药品发展高级副总裁。自2011年1月至2012年3月任药物临床安全部副董事长，自2010年1月至2011年1月任药物毒品学副董事长，自2008年1月至2010年1月任药物毒品学高级董事长。自2002年3月至2008年1月Chanda博士成为Neurogesx药品发展公司高级管理人员，管理公司药品发展。在加入Neurogesx公司之前，自1999年2月至2002年2月Chanda博士在Cerus制药公司担任各类毒物学要职。他获得伯拉科学技术学院医学理学学士学位，药品理学硕士学位，现在获得门罗东北路易斯安那大学医药毒品学博士学位。
Sanjay Chanda,served as the Chief Development Officer at Cortene lnc., a biopharmaceutical company. Since January 2014, Dr. Chanda has also served as the Co-Founder and Development Consultant at Auration Biotech, Inc., a pharmaceutical company. From October 2016 to August 2017, he served as the Chief Development Officer of Tioma Therapeutics, Inc., an immune-oncology company. From January 2008 to October 2016, Dr. Chanda served as the Senior Vice President of Drug Development of Anacor. Dr. Chanda received a Ph.D. in Pharmacology and Toxicology from Northeast Louisiana University and an M. Pharmacy and B. Pharmacy from Birla Institute of Technology, Mesra, India.- Sanjay Chanda，博士。自2012年3月至2013年10月任中期药品发展公司副总裁一职，随后自2013年10月成为药品发展高级副总裁。自2011年1月至2012年3月任药物临床安全部副董事长，自2010年1月至2011年1月任药物毒品学副董事长，自2008年1月至2010年1月任药物毒品学高级董事长。自2002年3月至2008年1月Chanda博士成为Neurogesx药品发展公司高级管理人员，管理公司药品发展。在加入Neurogesx公司之前，自1999年2月至2002年2月Chanda博士在Cerus制药公司担任各类毒物学要职。他获得伯拉科学技术学院医学理学学士学位，药品理学硕士学位，现在获得门罗东北路易斯安那大学医药毒品学博士学位。
- Sanjay Chanda,served as the Chief Development Officer at Cortene lnc., a biopharmaceutical company. Since January 2014, Dr. Chanda has also served as the Co-Founder and Development Consultant at Auration Biotech, Inc., a pharmaceutical company. From October 2016 to August 2017, he served as the Chief Development Officer of Tioma Therapeutics, Inc., an immune-oncology company. From January 2008 to October 2016, Dr. Chanda served as the Senior Vice President of Drug Development of Anacor. Dr. Chanda received a Ph.D. in Pharmacology and Toxicology from Northeast Louisiana University and an M. Pharmacy and B. Pharmacy from Birla Institute of Technology, Mesra, India.